<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32487123</PMID><DateCompleted><Year>2021</Year><Month>07</Month><Day>01</Day></DateCompleted><DateRevised><Year>2021</Year><Month>07</Month><Day>01</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1750-1326</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>1</Issue><PubDate><Year>2020</Year><Month>Jun</Month><Day>01</Day></PubDate></JournalIssue><Title>Molecular neurodegeneration</Title><ISOAbbreviation>Mol Neurodegener</ISOAbbreviation></Journal><ArticleTitle>From basic research to the clinic: innovative therapies for ALS and FTD in the pipeline.</ArticleTitle><Pagination><StartPage>31</StartPage><MedlinePgn>31</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">31</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13024-020-00373-9</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) and Frontotemporal Degeneration (FTD) are neurodegenerative disorders, related by deterioration of motor and cognitive functions and short survival. Aside from cases with an inherited pathogenic mutation, the causes of the disorders are still largely unknown and no effective treatment currently exists. It has been shown that FTD may coexist with ALS and this overlap occurs at clinical, genetic, and molecular levels. In this work, we review the main pathological aspects of these complex diseases and discuss how the integration of the novel pathogenic molecular insights and the analysis of molecular interaction networks among all the genetic players represents a critical step to shed light on discovering novel therapeutic strategies and possibly tailoring personalized medicine approaches to specific ALS and FTD patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Liscic</LastName><ForeName>Rajka Maria</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Johannes Kepler University, Linz, Austria.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, University of Osijek, Osijek, Croatia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alberici</LastName><ForeName>Antonella</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Neurology Unit, Department of Neurological Sciences and Vision, ASST-Spedali Civili-University of Brescia, Brescia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cairns</LastName><ForeName>Nigel John</ForeName><Initials>NJ</Initials><AffiliationInfo><Affiliation>College of Medicine and Health and Living Systems Institute, University of Exeter, Exeter, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Romano</LastName><ForeName>Maurizio</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Life Sciences, Via Valerio 28, University of Trieste, 34127, Trieste, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buratti</LastName><ForeName>Emanuele</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>International Centre for Genetic Engineering and Biotechnology (ICGEB), Padriciano 99, 34149, Trieste, Italy. buratti@icgeb.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>06</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Mol Neurodegener</MedlineTA><NlmUniqueID>101266600</NlmUniqueID><ISSNLinking>1750-1326</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001284" MajorTopicYN="N">Atrophy</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="N">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D035703" MajorTopicYN="Y">Therapies, Investigational</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS</Keyword><Keyword MajorTopicYN="N">Dementia FTLD</Keyword><Keyword MajorTopicYN="N">FTD</Keyword><Keyword MajorTopicYN="N">Genetics</Keyword><Keyword MajorTopicYN="N">Motor neuron disease TDP-43</Keyword><Keyword MajorTopicYN="N">Stem cell</Keyword></KeywordList><CoiStatement>All Authors declare no competing conflict of interest and declare no financial or personal relationship with organizations that could potentially be perceived as influencing the described research.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>12</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>3</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>6</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>6</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>7</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32487123</ArticleId><ArticleId IdType="pmc">PMC7268618</ArticleId><ArticleId IdType="doi">10.1186/s13024-020-00373-9</ArticleId><ArticleId IdType="pii">10.1186/s13024-020-00373-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Logroscino G, Traynor BJ, Hardiman O, Chio A, Mitchell D, Swingler RJ, Millul A, Benn E, Beghi E. Eurals Incidence of amyotrophic lateral sclerosis in Europe. J Neurol Neurosurg Psychiatry. 2010;81(4):385&#x2013;390.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2850819</ArticleId><ArticleId IdType="pubmed">19710046</ArticleId></ArticleIdList></Reference><Reference><Citation>Mercy L, Hodges JR, Dawson K, Barker RA, Brayne C. Incidence of early-onset dementias in Cambridgeshire, United Kingdom. Neurology. 2008;71(19):1496&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">18981371</ArticleId></ArticleIdList></Reference><Reference><Citation>Karageorgiou E, Miller BL. Frontotemporal lobar degeneration: a clinical approach. Semin Neurol. 2014;34:189&#x2013;201.</Citation><ArticleIdList><ArticleId IdType="pubmed">24963678</ArticleId></ArticleIdList></Reference><Reference><Citation>Olney NT, Spina S, Miller BL. Frontotemporal Dementia. Neurol Clin. 2017;35(2):339&#x2013;374.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5472209</ArticleId><ArticleId IdType="pubmed">28410663</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan XD, Chen XC. Clinic, neuropathology and molecular genetics of frontotemporal dementia: a mini-review. Transl Neurodegener. 2013;2(1):8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3639184</ArticleId><ArticleId IdType="pubmed">23597030</ArticleId></ArticleIdList></Reference><Reference><Citation>Saberi S, Stauffer JE, Schulte DJ, Ravits J. Neuropathology of Amyotrophic Lateral Sclerosis and Its Variants. Neurol Clin. 2015;33(4):855&#x2013;876.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4628785</ArticleId><ArticleId IdType="pubmed">26515626</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass C, Neumann M. Frontotemporal dementia: from molecular mechanisms to therapy. J Neurochem. 2016;138(Suppl 1):3&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">27502123</ArticleId></ArticleIdList></Reference><Reference><Citation>Woollacott IO, Rohrer JD. The clinical spectrum of sporadic and familial forms of frontotemporal dementia. J Neurochem. 2016;138(Suppl 1):6&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">27144467</ArticleId></ArticleIdList></Reference><Reference><Citation>Tard C, Defebvre L, Moreau C, Devos D, Danel-Brunaud V. Clinical features of amyotrophic lateral sclerosis and their prognostic value. Rev Neurol (Paris) 2017;173(5):263&#x2013;272.</Citation><ArticleIdList><ArticleId IdType="pubmed">28477850</ArticleId></ArticleIdList></Reference><Reference><Citation>Peteri UK, Niukkanen M, Castren ML. Astrocytes in Neuropathologies Affecting the Frontal Cortex. Front Cell Neurosci. 2019;13:44.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6379461</ArticleId><ArticleId IdType="pubmed">30809131</ArticleId></ArticleIdList></Reference><Reference><Citation>Oeckl P, Weydt P, Steinacker P, Anderl-Straub S, Nordin F, Volk AE, Diehl-Schmid J, Andersen PM, Kornhuber J, Danek A, et al. Different neuroinflammatory profile in amyotrophic lateral sclerosis and frontotemporal dementia is linked to the clinical phase. J Neurol Neurosurg Psychiatry. 2019;90(1):4&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">30224549</ArticleId></ArticleIdList></Reference><Reference><Citation>McCauley ME, Baloh RH. Inflammation in ALS/FTD pathogenesis. Acta Neuropathol. 2019;137(5):715&#x2013;730.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6482122</ArticleId><ArticleId IdType="pubmed">30465257</ArticleId></ArticleIdList></Reference><Reference><Citation>Strong MJ, Grace GM, Freedman M, Lomen-Hoerth C, Woolley S, Goldstein LH, Murphy J, Shoesmith C, Rosenfeld J, Leigh PN, et al. Consensus criteria for the diagnosis of frontotemporal cognitive and behavioural syndromes in amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2009;10(3):131&#x2013;146.</Citation><ArticleIdList><ArticleId IdType="pubmed">19462523</ArticleId></ArticleIdList></Reference><Reference><Citation>Grossman M. Amyotrophic lateral sclerosis - a multisystem neurodegenerative disorder. Nat Rev Neurol. 2019;15(1):5&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">30446736</ArticleId></ArticleIdList></Reference><Reference><Citation>Cairns NJ, Bigio EH, Mackenzie IR, Neumann M, Lee VM, Hatanpaa KJ, White CL, 3rd, Schneider JA, Grinberg LT, Halliday G, et al. Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. Acta Neuropathol. 2007;114(1):5&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2827877</ArticleId><ArticleId IdType="pubmed">17579875</ArticleId></ArticleIdList></Reference><Reference><Citation>Mejzini R, Flynn LL, Pitout IL, Fletcher S, Wilton SD, Akkari PA. ALS Genetics, Mechanisms, and Therapeutics: Where Are We Now? Front Neurosci. 2019;13:1310.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6909825</ArticleId><ArticleId IdType="pubmed">31866818</ArticleId></ArticleIdList></Reference><Reference><Citation>Pottier C, Ravenscroft TA, Sanchez-Contreras M, Rademakers R. Genetics of FTLD: overview and what else we can expect from genetic studies. J Neurochem. 2016;138(Suppl 1):32&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">27009575</ArticleId></ArticleIdList></Reference><Reference><Citation>Alsultan AA, Waller R, Heath PR, Kirby J. The genetics of amyotrophic lateral sclerosis: current insights. Degener Neurol Neuromuscul Dis. 2016;6:49&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6053097</ArticleId><ArticleId IdType="pubmed">30050368</ArticleId></ArticleIdList></Reference><Reference><Citation>DeJesus-Hernandez M, Mackenzie IR, Boeve BF, Boxer AL, Baker M, Rutherford NJ, Nicholson AM, Finch NA, Flynn H, Adamson J, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011;72(2):245&#x2013;256.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3202986</ArticleId><ArticleId IdType="pubmed">21944778</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE, Majounie E, Waite A, Simon-Sanchez J, Rollinson S, Gibbs JR, Schymick JC, Laaksovirta H, van Swieten JC, Myllykangas L, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 2011;72(2):257&#x2013;268.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3200438</ArticleId><ArticleId IdType="pubmed">21944779</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, Hentati A, Donaldson D, Goto J, O'Regan JP, Deng HX, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 1993;362(6415):59&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">8446170</ArticleId></ArticleIdList></Reference><Reference><Citation>Arai T, Hasegawa M, Akiyama H, Ikeda K, Nonaka T, Mori H, Mann D, Tsuchiya K, Yoshida M, Hashizume Y, Oda T. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun. 2006;351(3):602&#x2013;611.</Citation><ArticleIdList><ArticleId IdType="pubmed">17084815</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, Bruce J, Schuck T, Grossman M, Clark CM, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314(5796):130&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwiatkowski TJ, Jr, Bosco DA, Leclerc AL, Tamrazian E, Vanderburg CR, Russ C, Davis A, Gilchrist J, Kasarskis EJ, Munsat T, et al. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science. 2009;323(5918):1205&#x2013;1208.</Citation><ArticleIdList><ArticleId IdType="pubmed">19251627</ArticleId></ArticleIdList></Reference><Reference><Citation>Vance C, Rogelj B, Hortobagyi T, De Vos KJ, Nishimura AL, Sreedharan J, Hu X, Smith B, Ruddy D, Wright P, et al. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science. 2009;323(5918):1208&#x2013;1211.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4516382</ArticleId><ArticleId IdType="pubmed">19251628</ArticleId></ArticleIdList></Reference><Reference><Citation>Volk AE, Weishaupt JH, Andersen PM, Ludolph AC, Kubisch C. Current knowledge and recent insights into the genetic basis of amyotrophic lateral sclerosis. Med Genet. 2018;30(2):252&#x2013;258.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6132774</ArticleId><ArticleId IdType="pubmed">30220791</ArticleId></ArticleIdList></Reference><Reference><Citation>Sirkis DW, Geier EG, Bonham LW, Karch CM, Yokoyama JS. Recent advances in the genetics of frontotemporal dementia. Curr Genet Med Rep. 2019;7(1):41&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6827567</ArticleId><ArticleId IdType="pubmed">31687268</ArticleId></ArticleIdList></Reference><Reference><Citation>Olszewska DA, Lonergan R, Fallon EM, Lynch T. Genetics of Frontotemporal Dementia. Curr Neurol Neurosci Rep. 2016;16(12):107.</Citation><ArticleIdList><ArticleId IdType="pubmed">27878525</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon DA, Mitchell JC, Salcher-Konrad MT, Vance CA, Mizielinska S. Review: Modelling the pathology and behaviour of frontotemporal dementia. Neuropathol Appl Neurobiol. 2019;45(1):58&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">30582188</ArticleId></ArticleIdList></Reference><Reference><Citation>Warde-Farley D, Donaldson SL, Comes O, Zuberi K, Badrawi R, Chao P, Franz M, Grouios C, Kazi F, Lopes CT, et al. The GeneMANIA prediction server: biological network integration for gene prioritization and predicting gene function. Nucleic Acids Res. 2010;38(Web Server issue):W214&#x2013;W220.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2896186</ArticleId><ArticleId IdType="pubmed">20576703</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuberi K, Franz M, Rodriguez H, Montojo J, Lopes CT, Bader GD, Morris Q. GeneMANIA prediction server 2013 update. Nucleic Acids Res. 2013;41(Web Server issue):W115&#x2013;W122.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3692113</ArticleId><ArticleId IdType="pubmed">23794635</ArticleId></ArticleIdList></Reference><Reference><Citation>Liscic RM, Breljak D. Molecular basis of amyotrophic lateral sclerosis. Prog Neuro-Psychopharmacol Biol Psychiatry. 2011;35(2):370&#x2013;372.</Citation><ArticleIdList><ArticleId IdType="pubmed">20655970</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng AS, Rademakers R, Miller BL. Frontotemporal dementia: a bridge between dementia and neuromuscular disease. Ann N Y Acad Sci. 2015;1338:71&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4399703</ArticleId><ArticleId IdType="pubmed">25557955</ArticleId></ArticleIdList></Reference><Reference><Citation>Liscic RM. Molecular basis of ALS and FTD: implications for translational studies. Arh Hig Rada Toksikol. 2015;66(4):285&#x2013;290.</Citation><ArticleIdList><ArticleId IdType="pubmed">26751860</ArticleId></ArticleIdList></Reference><Reference><Citation>Liscic RM, Grinberg LT, Zidar J, Gitcho MA, Cairns NJ. ALS and FTLD: two faces of TDP-43 proteinopathy. Eur J Neurol. 2008;15(8):772&#x2013;780.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2801606</ArticleId><ArticleId IdType="pubmed">18684309</ArticleId></ArticleIdList></Reference><Reference><Citation>Hergesheimer RC, Chami AA, de Assis DR, Vourc'h P, Andres CR, Corcia P, Lanznaster D, Blasco H. The debated toxic role of aggregated TDP-43 in amyotrophic lateral sclerosis: a resolution in sight? Brain. 2019;142(5):1176&#x2013;1194.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6487324</ArticleId><ArticleId IdType="pubmed">30938443</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett CL, Dastidar SG, Ling SC, Malik B, Ashe T, Wadhwa M, Miller DB, Lee C, Mitchell MB, van Es MA, et al. Senataxin mutations elicit motor neuron degeneration phenotypes and yield TDP-43 mislocalization in ALS4 mice and human patients. Acta Neuropathol. 2018;136(3):425&#x2013;443.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6098723</ArticleId><ArticleId IdType="pubmed">29725819</ArticleId></ArticleIdList></Reference><Reference><Citation>Elden AC, Kim HJ, Hart MP, Chen-Plotkin AS, Johnson BS, Fang X, Armakola M, Geser F, Greene R, Lu MM, et al. Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature. 2010;466(7310):1069&#x2013;1075.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2965417</ArticleId><ArticleId IdType="pubmed">20740007</ArticleId></ArticleIdList></Reference><Reference><Citation>Sumi H, Kato S, Mochimaru Y, Fujimura H, Etoh M, Sakoda S. Nuclear TAR DNA binding protein 43 expression in spinal cord neurons correlates with the clinical course in amyotrophic lateral sclerosis. J Neuropathol Exp Neurol. 2009;68(1):37&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pubmed">19104447</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeon GS, Shim YM, Lee DY, Kim JS, Kang M, Ahn SH, Shin JY, Geum D, Hong YH, Sung JJ. Pathological Modification of TDP-43 in Amyotrophic Lateral Sclerosis with SOD1 Mutations. Mol Neurobiol. 2019;56(3):2007&#x2013;2021.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6394608</ArticleId><ArticleId IdType="pubmed">29982983</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirby J, Highley JR, Cox L, Goodall EF, Hewitt C, Hartley JA, Hollinger HC, Fox M, Ince PG, McDermott CJ, Shaw PJ. Lack of unique neuropathology in amyotrophic lateral sclerosis associated with p.K54E angiogenin (ANG) mutation. Neuropathol Appl Neurobiol. 2013;39(5):562&#x2013;571.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3770927</ArticleId><ArticleId IdType="pubmed">23228179</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Zee J, Van Langenhove T, Kovacs GG, Dillen L, Deschamps W, Engelborghs S, Matej R, Vandenbulcke M, Sieben A, Dermaut B, et al. Rare mutations in SQSTM1 modify susceptibility to frontotemporal lobar degeneration. Acta Neuropathol. 2014;128(3):397&#x2013;410.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4131163</ArticleId><ArticleId IdType="pubmed">24899140</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson JO, Pioro EP, Boehringer A, Chia R, Feit H, Renton AE, Pliner HA, Abramzon Y, Marangi G, Winborn BJ, et al. Mutations in the Matrin 3 gene cause familial amyotrophic lateral sclerosis. Nat Neurosci. 2014;17(5):664&#x2013;666.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4000579</ArticleId><ArticleId IdType="pubmed">24686783</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim HJ, Kim NC, Wang YD, Scarborough EA, Moore J, Diaz Z, MacLea KS, Freibaum B, Li S, Molliex A, et al. Mutations in prion-like domains in hnRNPA2B1 and hnRNPA1 cause multisystem proteinopathy and ALS. Nature. 2013;495(7442):467&#x2013;473.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3756911</ArticleId><ArticleId IdType="pubmed">23455423</ArticleId></ArticleIdList></Reference><Reference><Citation>Purice MD, Taylor JP. Linking hnRNP Function to ALS and FTD Pathology. Front Neurosci. 2018;12:326.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5962818</ArticleId><ArticleId IdType="pubmed">29867335</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamada M, Izumi Y, Ayaki T, Nakamura M, Kagawa S, Kudo E, Sako W, Maruyama H, Nishida Y, Kawakami H, et al. Clinicopathologic features of autosomal recessive amyotrophic lateral sclerosis associated with optineurin mutation. Neuropathology. 2014;34(1):64&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">23889540</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith BN, Ticozzi N, Fallini C, Gkazi AS, Topp S, Kenna KP, Scotter EL, Kost J, Keagle P, Miller JW, et al. Exome-wide rare variant analysis identifies TUBA4A mutations associated with familial ALS. Neuron. 2014;84(2):324&#x2013;331.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4521390</ArticleId><ArticleId IdType="pubmed">25374358</ArticleId></ArticleIdList></Reference><Reference><Citation>Kabashi E, Valdmanis PN, Dion P, Spiegelman D, McConkey BJ, Vande Velde C, Bouchard JP, Lacomblez L, Pochigaeva K, Salachas F, et al. TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. Nat Genet. 2008;40(5):572&#x2013;574.</Citation><ArticleIdList><ArticleId IdType="pubmed">18372902</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Deerlin VM, Leverenz JB, Bekris LM, Bird TD, Yuan W, Elman LB, Clay D, Wood EM, Chen-Plotkin AS, Martinez-Lage M, et al. TARDBP mutations in amyotrophic lateral sclerosis with TDP-43 neuropathology: a genetic and histopathological analysis. Lancet Neurol. 2008;7(5):409&#x2013;416.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3546119</ArticleId><ArticleId IdType="pubmed">18396105</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon DA, Stepto A, Au WH, Adachi Y, Diaper DC, Hall R, Rekhi A, Boudi A, Tziortzouda P, Lee YB, et al. A feedback loop between dipeptide-repeat protein, TDP-43 and karyopherin-alpha mediates C9orf72-related neurodegeneration. Brain. 2018;141(10):2908&#x2013;2924.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6158706</ArticleId><ArticleId IdType="pubmed">30239641</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SM, Asress S, Hales CM, Gearing M, Vizcarra JC, Fournier CN, Gutman DA, Chin LS, Li L, Glass JD. TDP-43 cytoplasmic inclusion formation is disrupted in C9orf72-associated amyotrophic lateral sclerosis/frontotemporal lobar degeneration. Brain Commun. 2019;1(1):fcz014.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6788139</ArticleId><ArticleId IdType="pubmed">31633109</ArticleId></ArticleIdList></Reference><Reference><Citation>Wider C, Dickson DW, Stoessl AJ, Tsuboi Y, Chapon F, Gutmann L, Lechevalier B, Calne DB, Personett DA, Hulihan M, et al. Pallidonigral TDP-43 pathology in Perry syndrome. Parkinsonism Relat Disord. 2009;15(4):281&#x2013;286.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2693935</ArticleId><ArticleId IdType="pubmed">18723384</ArticleId></ArticleIdList></Reference><Reference><Citation>Gijselinck I, Van Mossevelde S, van der Zee J, Sieben A, Philtjens S, Heeman B, Engelborghs S, Vandenbulcke M, De Baets G, Baumer V, et al. Loss of TBK1 is a frequent cause of frontotemporal dementia in a Belgian cohort. Neurology. 2015;85(24):2116&#x2013;2125.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4691687</ArticleId><ArticleId IdType="pubmed">26581300</ArticleId></ArticleIdList></Reference><Reference><Citation>Woo JA, Liu T, Trotter C, Fang CC, De Narvaez E, LePochat P, Maslar D, Bukhari A, Zhao X, Deonarine A, et al. Loss of function CHCHD10 mutations in cytoplasmic TDP-43 accumulation and synaptic integrity. Nat Commun. 2017;8(1):15558.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5467170</ArticleId><ArticleId IdType="pubmed">28585542</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams KL, Topp S, Yang S, Smith B, Fifita JA, Warraich ST, Zhang KY, Farrawell N, Vance C, Hu X, et al. CCNF mutations in amyotrophic lateral sclerosis and frontotemporal dementia. Nat Commun. 2016;7(1):11253.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4835537</ArticleId><ArticleId IdType="pubmed">27080313</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng HX, Chen W, Hong ST, Boycott KM, Gorrie GH, Siddique N, Yang Y, Fecto F, Shi Y, Zhai H, et al. Mutations in UBQLN2 cause dominant X-linked juvenile and adult-onset ALS and ALS/dementia. Nature. 2011;477(7363):211&#x2013;215.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3169705</ArticleId><ArticleId IdType="pubmed">21857683</ArticleId></ArticleIdList></Reference><Reference><Citation>Holm IE, Englund E, Mackenzie IR, Johannsen P, Isaacs AM. A reassessment of the neuropathology of frontotemporal dementia linked to chromosome 3. J Neuropathol Exp Neurol. 2007;66(10):884&#x2013;891.</Citation><ArticleIdList><ArticleId IdType="pubmed">17917582</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, Mackenzie IR, Cairns NJ, Boyer PJ, Markesbery WR, Smith CD, Taylor JP, Kretzschmar HA, Kimonis VE, Forman MS. TDP-43 in the ubiquitin pathology of frontotemporal dementia with VCP gene mutations. J Neuropathol Exp Neurol. 2007;66(2):152&#x2013;157.</Citation><ArticleIdList><ArticleId IdType="pubmed">17279000</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IR. The neuropathology and clinical phenotype of FTD with progranulin mutations. Acta Neuropathol. 2007;114(1):49&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">17458552</ArticleId></ArticleIdList></Reference><Reference><Citation>Jun MH, Han JH, Lee YK, Jang DJ, Kaang BK, Lee JA. TMEM106B, a frontotemporal lobar dementia (FTLD) modifier, associates with FTD-3-linked CHMP2B, a complex of ESCRT-III. Mol Brain. 2015;8(1):85.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4676093</ArticleId><ArticleId IdType="pubmed">26651479</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, Mackenzie IRA. Review: Neuropathology of non-tau frontotemporal lobar degeneration. Neuropathol Appl Neurobiol. 2019;45(1):19&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">30357887</ArticleId></ArticleIdList></Reference><Reference><Citation>Amador-Ortiz C, Lin WL, Ahmed Z, Personett D, Davies P, Duara R, Graff-Radford NR, Hutton ML, Dickson DW. TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer's disease. Ann Neurol. 2007;61(5):435&#x2013;445.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2677204</ArticleId><ArticleId IdType="pubmed">17469117</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasegawa M, Arai T, Akiyama H, Nonaka T, Mori H, Hashimoto T, Yamazaki M, Oyanagi K. Book TDP-43 is deposited in the Guam parkinsonism-dementia complex brains. - PubMed - NCBI (Editor ed.^eds.) 2007. TDP-43 is deposited in the Guam parkinsonism-dementia complex brains. - PubMed - NCBI; pp. 1386&#x2013;1394.</Citation><ArticleIdList><ArticleId IdType="pubmed">17439983</ArticleId></ArticleIdList></Reference><Reference><Citation>Higashi S, Iseki E, Yamamoto R, Minegishi M, Hino H, Fujisawa K, Togo T, Katsuse O, Uchikado H, Furukawa Y, et al. Concurrence of TDP-43, tau and alpha-synuclein pathology in brains of Alzheimer's disease and dementia with Lewy bodies. Brain Res. 2007;1184:284&#x2013;294.</Citation><ArticleIdList><ArticleId IdType="pubmed">17963732</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalmar B, Lu CH, Greensmith L. Book The role of heat shock proteins in Amyotrophic Lateral Sclerosis: The therapeutic potential of Arimoclomol (Editor ed.^eds.) 2014. The role of heat shock proteins in Amyotrophic Lateral Sclerosis: The therapeutic potential of Arimoclomol; pp. 40&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">23978556</ArticleId></ArticleIdList></Reference><Reference><Citation>Koga S, Sanchez-Contreras M, Josephs KA, Uitti RJ, Graff-Radford N, van Gerpen JA, Cheshire WP, Wszolek ZK, Rademakers R, Dickson DW. Distribution and characteristics of transactive response DNA binding protein 43 kDa pathology in progressive supranuclear palsy. Mov Disord. 2017;32(2):246&#x2013;255.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5933946</ArticleId><ArticleId IdType="pubmed">28009087</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin WL, Dickson DW. Ultrastructural localization of TDP-43 in filamentous neuronal inclusions in various neurodegenerative diseases. Acta Neuropathol. 2008;116(2):205&#x2013;213.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2706695</ArticleId><ArticleId IdType="pubmed">18607609</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakashima-Yasuda H, Uryu K, Robinson J, Xie SX, Hurtig H, Duda JE, Arnold SE, Siderowf A, Grossman M, Leverenz JB, et al. Co-morbidity of TDP-43 proteinopathy in Lewy body related diseases. Acta Neuropathol. 2007;114(3):221&#x2013;229.</Citation><ArticleIdList><ArticleId IdType="pubmed">17653732</ArticleId></ArticleIdList></Reference><Reference><Citation>Uryu K, Nakashima-Yasuda H, Forman MS, Kwong LK, Clark CM, Grossman M, Miller BL, Kretzschmar HA, Lee VM, Trojanowski JQ, Neumann M. Concomitant TAR-DNA-binding protein 43 pathology is present in Alzheimer disease and corticobasal degeneration but not in other tauopathies. J Neuropathol Exp Neurol. 2008;67(6):555&#x2013;564.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3659339</ArticleId><ArticleId IdType="pubmed">18520774</ArticleId></ArticleIdList></Reference><Reference><Citation>Dugger BN, Dickson DW. Pathology of neurodegenerative diseases. Cold Spring Harb Perspect Biol. 2017;9(7):a028035.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5495060</ArticleId><ArticleId IdType="pubmed">28062563</ArticleId></ArticleIdList></Reference><Reference><Citation>Dardis A, Zampieri S, Canterini S, Newell KL, Stuani C, Murrell JR, Ghetti B, Fiorenza MT, Bembi B, Buratti E. Altered localization and functionality of TAR DNA Binding Protein 43 (TDP-43) in niemann- pick disease type C. Acta Neuropathol Commun. 2016;4(1):52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4870731</ArticleId><ArticleId IdType="pubmed">27193329</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrari R, Kapogiannis D, Huey ED, Momeni P. FTD and ALS: a tale of two diseases. Curr Alzheimer Res. 2011;8(3):273&#x2013;294.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3801195</ArticleId><ArticleId IdType="pubmed">21222600</ArticleId></ArticleIdList></Reference><Reference><Citation>De Benedetti S, Lucchini G, Del Bo C, Deon V, Marocchi A, Penco S, Lunetta C, Gianazza E, Bonomi F, Iametti S. Blood trace metals in a sporadic amyotrophic lateral sclerosis geographical cluster. Biometals. 2017;30(3):355&#x2013;365.</Citation><ArticleIdList><ArticleId IdType="pubmed">28337565</ArticleId></ArticleIdList></Reference><Reference><Citation>Cicero CE, Mostile G, Vasta R, Rapisarda V, Signorelli SS, Ferrante M, Zappia M, Nicoletti A. Metals and neurodegenerative diseases. A systematic review. Environ Res. 2017;159:82&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">28777965</ArticleId></ArticleIdList></Reference><Reference><Citation>Jimenez-Pacheco A, Franco JM, Lopez S, Gomez-Zumaquero JM, Magdalena Leal-Lasarte M, Caballero-Hernandez DE, Cejudo-Guillen M, Pozo D. Epigenetic Mechanisms of Gene Regulation in Amyotrophic Lateral Sclerosis. Adv Exp Med Biol. 2017;978:255&#x2013;275.</Citation><ArticleIdList><ArticleId IdType="pubmed">28523551</ArticleId></ArticleIdList></Reference><Reference><Citation>Belzil VV, Katzman RB, Petrucelli L. ALS and FTD: an epigenetic perspective. Acta Neuropathol. 2016;132(4):487&#x2013;502.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5138862</ArticleId><ArticleId IdType="pubmed">27282474</ArticleId></ArticleIdList></Reference><Reference><Citation>Oates N, Pamphlett R. An epigenetic analysis of SOD1 and VEGF in ALS. Amyotroph Lateral Scler. 2007;8(2):83&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">17453634</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y, Gozen O, Vidensky S, Robinson MB, Rothstein JD. Epigenetic regulation of neuron-dependent induction of astroglial synaptic protein GLT1. Glia. 2010;58(3):277&#x2013;286.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2794958</ArticleId><ArticleId IdType="pubmed">19672971</ArticleId></ArticleIdList></Reference><Reference><Citation>Kioumourtzoglou MA, Rotem RS, Seals RM, Gredal O, Hansen J, Weisskopf MG. Diabetes Mellitus, Obesity, and Diagnosis of Amyotrophic Lateral Sclerosis: A Population-Based Study. JAMA Neurol. 2015;72(8):905&#x2013;911.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4975611</ArticleId><ArticleId IdType="pubmed">26030836</ArticleId></ArticleIdList></Reference><Reference><Citation>Manera U, D&#x2019;Ovidio F, D&#x2019;Errico A, Carn&#xe0; P, Calvo A, Costa G, Chi&#xf2; A. The role of pre-morbid diabetes on developing ALS: a population-based study (P6.462) Neurology. 2018;90(15 Supplement):P6.462.</Citation></Reference><Reference><Citation>Jawaid A, Khan R, Polymenidou M, Schulz PE. Disease-modifying effects of metabolic perturbations in ALS/FTLD. Mol Neurodegener. 2018;13(1):63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6278047</ArticleId><ArticleId IdType="pubmed">30509290</ArticleId></ArticleIdList></Reference><Reference><Citation>Jawaid A, Paganoni S, Hauser C, Schulz PE. Trials of antidiabetic drugs in amyotrophic lateral sclerosis: proceed with caution? Neurodegener Dis. 2014;13(4):205&#x2013;208.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4435550</ArticleId><ArticleId IdType="pubmed">24107404</ArticleId></ArticleIdList></Reference><Reference><Citation>Jawaid A, Poon M, Strutt AM, Rice LK, McDowell EJ, Salamone AR, Qureshi SU, Simpson E, Appel SH, York MK, Schulz PE. Does apolipoprotein E genotype modify the clinical expression of ALS? Eur J Neurol. 2011;18(4):618&#x2013;624.</Citation><ArticleIdList><ArticleId IdType="pubmed">20880000</ArticleId></ArticleIdList></Reference><Reference><Citation>Jawaid A, Salamone AR, Strutt AM, Murthy SB, Wheaton M, McDowell EJ, Simpson E, Appel SH, York MK, Schulz PE. ALS disease onset may occur later in patients with pre-morbid diabetes mellitus. Eur J Neurol. 2010;17(5):733&#x2013;739.</Citation><ArticleIdList><ArticleId IdType="pubmed">20074230</ArticleId></ArticleIdList></Reference><Reference><Citation>Jawaid A, Murthy SB, Wilson AM, Qureshi SU, Amro MJ, Wheaton M, Simpson E, Harati Y, Strutt AM, York MK, Schulz PE. A decrease in body mass index is associated with faster progression of motor symptoms and shorter survival in ALS. Amyotroph Lateral Scler. 2010;11(6):542&#x2013;548.</Citation><ArticleIdList><ArticleId IdType="pubmed">20500116</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenfeld J, Ellis A. Nutrition and dietary supplements in motor neuron disease. Phys Med Rehabil Clin N Am. 2008;19(3):573&#x2013;589.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2631353</ArticleId><ArticleId IdType="pubmed">18625417</ArticleId></ArticleIdList></Reference><Reference><Citation>Nieves JW, Gennings C, Factor-Litvak P, Hupf J, Singleton J, Sharf V, Oskarsson B, Fernandes Filho JA, Sorenson EJ, D'Amico E, et al. Association Between Dietary Intake and Function in Amyotrophic Lateral Sclerosis. JAMA Neurol. 2016;73(12):1425&#x2013;1432.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5370581</ArticleId><ArticleId IdType="pubmed">27775751</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang LP, Fan DS. Diets for Patients with Amyotrophic Lateral Sclerosis: Pay Attention to Nutritional Intervention. Chin Med J. 2017;130(15):1765&#x2013;1767.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5547825</ArticleId><ArticleId IdType="pubmed">28748846</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Chalabi A. High-calorie diets in amyotrophic lateral sclerosis. Lancet. 2014;383(9934):2028&#x2013;2030.</Citation><ArticleIdList><ArticleId IdType="pubmed">24582470</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouteloup C, Desport JC, Clavelou P, Guy N, Derumeaux-Burel H, Ferrier A, Couratier P. Hypermetabolism in ALS patients: an early and persistent phenomenon. J Neurol. 2009;256(8):1236&#x2013;1242.</Citation><ArticleIdList><ArticleId IdType="pubmed">19306035</ArticleId></ArticleIdList></Reference><Reference><Citation>Dupuis L, Oudart H, Rene F, Gonzalez de Aguilar JL, Loeffler JP. Evidence for defective energy homeostasis in amyotrophic lateral sclerosis: benefit of a high-energy diet in a transgenic mouse model. Proc Natl Acad Sci U S A. 2004;101(30):11159&#x2013;11164.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC503756</ArticleId><ArticleId IdType="pubmed">15263088</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu F, Padukkavidana T, Vaegter CB, Brady OA, Zheng Y, Mackenzie IR, Feldman HH, Nykjaer A, Strittmatter SM. Sortilin-mediated endocytosis determines levels of the frontotemporal dementia protein, progranulin. Neuron. 2010;68(4):654&#x2013;667.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2990962</ArticleId><ArticleId IdType="pubmed">21092856</ArticleId></ArticleIdList></Reference><Reference><Citation>Carrasquillo MM, Nicholson AM, Finch N, Gibbs JR, Baker M, Rutherford NJ, Hunter TA, DeJesus-Hernandez M, Bisceglio GD, Mackenzie IR, et al. Genome-wide screen identifies rs646776 near sortilin as a regulator of progranulin levels in human plasma. Am J Hum Genet. 2010;87(6):890&#x2013;897.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2997361</ArticleId><ArticleId IdType="pubmed">21087763</ArticleId></ArticleIdList></Reference><Reference><Citation>Finch N, Carrasquillo MM, Baker M, Rutherford NJ, Coppola G, Dejesus-Hernandez M, Crook R, Hunter T, Ghidoni R, Benussi L, et al. TMEM106B regulates progranulin levels and the penetrance of FTLD in GRN mutation carriers. Neurology. 2011;76(5):467&#x2013;474.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3034409</ArticleId><ArticleId IdType="pubmed">21178100</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruchaga C, Graff C, Chiang HH, Wang J, Hinrichs AL, Spiegel N, Bertelsen S, Mayo K, Norton JB, Morris JC, Goate A. Association of TMEM106B gene polymorphism with age at onset in granulin mutation carriers and plasma granulin protein levels. Arch Neurol. 2011;68(5):581&#x2013;586.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3090529</ArticleId><ArticleId IdType="pubmed">21220649</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallagher MD, Suh E, Grossman M, Elman L, McCluskey L, Van Swieten JC, Al-Sarraj S, Neumann M, Gelpi E, Ghetti B, et al. TMEM106B is a genetic modifier of frontotemporal lobar degeneration with C9orf72 hexanucleotide repeat expansions. Acta Neuropathol. 2014;127(3):407&#x2013;418.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4003885</ArticleId><ArticleId IdType="pubmed">24442578</ArticleId></ArticleIdList></Reference><Reference><Citation>van Blitterswijk M, Mullen B, Wojtas A, Heckman MG, Diehl NN, Baker MC, DeJesus-Hernandez M, Brown PH, Murray ME, Hsiung GY, et al. Genetic modifiers in carriers of repeat expansions in the C9ORF72 gene. Mol Neurodegener. 2014;9:38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4190282</ArticleId><ArticleId IdType="pubmed">25239657</ArticleId></ArticleIdList></Reference><Reference><Citation>Vass R, Ashbridge E, Geser F, Hu WT, Grossman M, Clay-Falcone D, Elman L, McCluskey L, Lee VM, Van Deerlin VM, et al. Risk genotypes at TMEM106B are associated with cognitive impairment in amyotrophic lateral sclerosis. Acta Neuropathol. 2011;121(3):373&#x2013;380.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3095217</ArticleId><ArticleId IdType="pubmed">21104415</ArticleId></ArticleIdList></Reference><Reference><Citation>Rhinn H, Abeliovich A. Differential Aging Analysis in Human Cerebral Cortex Identifies Variants in TMEM106B and GRN that Regulate Aging Phenotypes. Cell Syst. 2017;4(4):404&#x2013;415.</Citation><ArticleIdList><ArticleId IdType="pubmed">28330615</ArticleId></ArticleIdList></Reference><Reference><Citation>White CC, Yang HS, Yu L, Chibnik LB, Dawe RJ, Yang J, Klein HU, Felsky D, Ramos-Miguel A, Arfanakis K, et al. Identification of genes associated with dissociation of cognitive performance and neuropathological burden: Multistep analysis of genetic, epigenetic, and transcriptional data. PLoS Med. 2017;14(4):e1002287.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5404753</ArticleId><ArticleId IdType="pubmed">28441426</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsumata Y, Nelson PT, Ellingson SR, Fardo DW. Gene-based association study of genes linked to hippocampal sclerosis of aging neuropathology: GRN, TMEM106B, ABCC9, and KCNMB2. Neurobiol Aging. 2017;53:193 e117&#x2013;193 e125.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5385271</ArticleId><ArticleId IdType="pubmed">28131462</ArticleId></ArticleIdList></Reference><Reference><Citation>Devenney E, Vucic S, Hodges JR, Kiernan MC. Motor neuron disease-frontotemporal dementia: a clinical continuum. Expert Rev Neurother. 2015;15(5):509&#x2013;522.</Citation><ArticleIdList><ArticleId IdType="pubmed">25865485</ArticleId></ArticleIdList></Reference><Reference><Citation>Boxer AL, Gold M, Huey E, Gao FB, Burton EA, Chow T, Kao A, Leavitt BR, Lamb B, Grether M, et al. Frontotemporal degeneration, the next therapeutic frontier: molecules and animal models for frontotemporal degeneration drug development. Alzheimers Dement. 2013;9(2):176&#x2013;188.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3542408</ArticleId><ArticleId IdType="pubmed">23043900</ArticleId></ArticleIdList></Reference><Reference><Citation>Hochgrafe K, Sydow A, Matenia D, Cadinu D, Konen S, Petrova O, Pickhardt M, Goll P, Morellini F, Mandelkow E, Mandelkow EM. Preventive methylene blue treatment preserves cognition in mice expressing full-length pro-aggregant human Tau. Acta Neuropathol Commun. 2015;3:25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4425867</ArticleId><ArticleId IdType="pubmed">25958115</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller RG, Rosenberg JA, Gelinas DF, Mitsumoto H, Newman D, Sufit R, Borasio GD, Bradley WG, Bromberg MB, Brooks BR, et al. Practice parameter: the care of the patient with amyotrophic lateral sclerosis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology: ALS Practice Parameters Task Force. Neurology. 1999;52(7):1311&#x2013;1323.</Citation><ArticleIdList><ArticleId IdType="pubmed">10227612</ArticleId></ArticleIdList></Reference><Reference><Citation>Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med. 1994;330(9):585&#x2013;591.</Citation><ArticleIdList><ArticleId IdType="pubmed">8302340</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet. 1996;347(9013):1425&#x2013;1431.</Citation><ArticleIdList><ArticleId IdType="pubmed">8676624</ArticleId></ArticleIdList></Reference><Reference><Citation>Dharmadasa T, Kiernan MC. Riluzole, disease stage and survival in ALS. Lancet Neurol. 2018;17(5):385&#x2013;386.</Citation><ArticleIdList><ArticleId IdType="pubmed">29525493</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheah BC, Vucic S, Krishnan AV, Kiernan MC. Riluzole, neuroprotection and amyotrophic lateral sclerosis. Curr Med Chem. 2010;17(18):1942&#x2013;1199.</Citation><ArticleIdList><ArticleId IdType="pubmed">20377511</ArticleId></ArticleIdList></Reference><Reference><Citation>Takei K, Watanabe K, Yuki S, Akimoto M, Sakata T, Palumbo J. Edaravone and its clinical development for amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18(sup1):5&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">28872907</ArticleId></ArticleIdList></Reference><Reference><Citation>Writing G, Edaravone ALSSG. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2017;16(7):505&#x2013;512.</Citation><ArticleIdList><ArticleId IdType="pubmed">28522181</ArticleId></ArticleIdList></Reference><Reference><Citation>Shefner J, Heiman-Patterson T, Pioro EP, Wiedau-Pazos M, Liu S, Zhang J, Agnese W, Apple S. Long-term edaravone efficacy in amyotrophic lateral sclerosis: Post-hoc analyses of Study 19 (MCI186-19) Muscle Nerve. 2020;61(2):218&#x2013;221.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7004197</ArticleId><ArticleId IdType="pubmed">31621933</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaiswal MK. Riluzole and edaravone: A tale of two amyotrophic lateral sclerosis drugs. Med Res Rev. 2019;39(2):733&#x2013;748.</Citation><ArticleIdList><ArticleId IdType="pubmed">30101496</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalmar B, Lu CH, Greensmith L. The role of heat shock proteins in Amyotrophic Lateral Sclerosis: The therapeutic potential of Arimoclomol. Pharmacol Ther. 2014;141(1):40&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">23978556</ArticleId></ArticleIdList></Reference><Reference><Citation>Kieran D, Kalmar B, Dick JR, Riddoch-Contreras J, Burnstock G, Greensmith L. Treatment with arimoclomol, a coinducer of heat shock proteins, delays disease progression in ALS mice. Nat Med. 2004;10(4):402&#x2013;405.</Citation><ArticleIdList><ArticleId IdType="pubmed">15034571</ArticleId></ArticleIdList></Reference><Reference><Citation>Scotter EL, Chen HJ, Shaw CE. TDP-43 Proteinopathy and ALS: Insights into Disease Mechanisms and Therapeutic Targets. Neurotherapeutics. 2015;12(2):352&#x2013;363.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4404432</ArticleId><ArticleId IdType="pubmed">25652699</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang P, Wander CM, Yuan CX, Bereman MS, Cohen TJ. Acetylation-induced TDP-43 pathology is suppressed by an HSF1-dependent chaperone program. Nat Commun. 2017;8(1):82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5517419</ArticleId><ArticleId IdType="pubmed">28724966</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M, Wuu J, Andersen PM, Atassi N, David W, Cudkowicz M, Schoenfeld D. Randomized, double-blind, placebo-controlled trial of arimoclomol in rapidly progressive SOD1 ALS. Neurology. 2018;90(7):e565&#x2013;e574.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5818014</ArticleId><ArticleId IdType="pubmed">29367439</ArticleId></ArticleIdList></Reference><Reference><Citation>Jagadapillai R, Mellen NM, Sachleben LR, Jr, Gozal E. Ceftriaxone preserves glutamate transporters and prevents intermittent hypoxia-induced vulnerability to brain excitotoxic injury. PLoS One. 2014;9(7):e100230.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4094429</ArticleId><ArticleId IdType="pubmed">25014412</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferraiuolo L, Kirby J, Grierson AJ, Sendtner M, Shaw PJ. Molecular pathways of motor neuron injury in amyotrophic lateral sclerosis. Nat Rev Neurol. 2011;7(11):616&#x2013;630.</Citation><ArticleIdList><ArticleId IdType="pubmed">22051914</ArticleId></ArticleIdList></Reference><Reference><Citation>Cudkowicz ME, Titus S, Kearney M, Yu H, Sherman A, Schoenfeld D, Hayden D, Shui A, Brooks B, Conwit R, et al. Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: a multi-stage, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2014;13(11):1083&#x2013;1091.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4216315</ArticleId><ArticleId IdType="pubmed">25297012</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammam K, Saez-Ayala M, Rebuffet E, Gros L, Lopez S, Hajem B, Humbert M, Baudelet E, Audebert S, Betzi S, et al. Dual protein kinase and nucleoside kinase modulators for rationally designed polypharmacology. Nat Commun. 2017;8(1):1420.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5681654</ArticleId><ArticleId IdType="pubmed">29127277</ArticleId></ArticleIdList></Reference><Reference><Citation>Mora JS, Genge A, Chio A, Estol CJ, Chaverri D, Hernandez M, Marin S, Mascias J, Rodriguez GE, Povedano M, et al. Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized clinical trial. Amyotroph Lateral Scler Frontotemporal Degener. 2020;21(1-2):5&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">31280619</ArticleId></ArticleIdList></Reference><Reference><Citation>Bilsland LG, Greensmith L. The endocannabinoid system in amyotrophic lateral sclerosis. Curr Pharm Des. 2008;14(23):2306&#x2013;2316.</Citation><ArticleIdList><ArticleId IdType="pubmed">18781981</ArticleId></ArticleIdList></Reference><Reference><Citation>Giacoppo S, Mazzon E. Can cannabinoids be a potential therapeutic tool in amyotrophic lateral sclerosis? Neural Regen Res. 2016;11(12):1896&#x2013;1899.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5270417</ArticleId><ArticleId IdType="pubmed">28197175</ArticleId></ArticleIdList></Reference><Reference><Citation>Urbi B, Owusu MA, Hughes I, Katz M, Broadley S, Sabet A. Effects of cannabinoids in Amyotrophic Lateral Sclerosis (ALS) murine models: a systematic review and meta-analysis. J Neurochem. 2019;149(2):284&#x2013;297.</Citation><ArticleIdList><ArticleId IdType="pubmed">30520038</ArticleId></ArticleIdList></Reference><Reference><Citation>Romano M, Buratti E. Tirasemtiv (CK-2017357) Drugs Future. 2013;38(3):157&#x2013;162.</Citation></Reference><Reference><Citation>Shefner JM, Cudkowicz ME, Hardiman O, Cockcroft BM, Lee JH, Malik FI, Meng L, Rudnicki SA, Wolff AA, Andrews JA, Group V-AS A phase III trial of tirasemtiv as a potential treatment for amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2019;0(0):1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">31081694</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrews JA, Cudkowicz ME, Hardiman O, Meng L, Bian A, Lee J, Wolff AA, Malik FI, Shefner JM. VITALITY-ALS, a phase III trial of tirasemtiv, a selective fast skeletal muscle troponin activator, as a potential treatment for patients with amyotrophic lateral sclerosis: study design and baseline characteristics. Amyotroph Lateral Scler Frontotemporal Degener. 2018;19(3-4):259&#x2013;266.</Citation><ArticleIdList><ArticleId IdType="pubmed">29402141</ArticleId></ArticleIdList></Reference><Reference><Citation>Hwee DT, Cheng AJ, Hartman JJ, Hinken AC, Lee K, Durham N, Russell AJ, Malik FI, Westerblad H, Jasper JR. The Ca(2+) sensitizer CK-2066260 increases myofibrillar Ca(2+) sensitivity and submaximal force selectively in fast skeletal muscle. J Physiol. 2017;595(5):1657&#x2013;1670.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5330873</ArticleId><ArticleId IdType="pubmed">27869319</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrews JA, Miller TM, Vijayakumar V, Stoltz R, James JK, Meng L, Wolff AA, Malik FI. CK-2127107 amplifies skeletal muscle response to nerve activation in humans. Muscle Nerve. 2018;57(5):729&#x2013;734.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6681065</ArticleId><ArticleId IdType="pubmed">29150952</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazzini L, Ferrero I, Luparello V, Rustichelli D, Gunetti M, Mareschi K, Testa L, Stecco A, Tarletti R, Miglioretti M, et al. Mesenchymal stem cell transplantation in amyotrophic lateral sclerosis: A Phase I clinical trial. Exp Neurol. 2010;223(1):229&#x2013;237.</Citation><ArticleIdList><ArticleId IdType="pubmed">19682989</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers DR, Appel SH. Immune dysregulation in amyotrophic lateral sclerosis: mechanisms and emerging therapies. Lancet Neurol. 2019;18(2):211&#x2013;220.</Citation><ArticleIdList><ArticleId IdType="pubmed">30663610</ArticleId></ArticleIdList></Reference><Reference><Citation>Glass JD, Hertzberg VS, Boulis NM, Riley J, Federici T, Polak M, Bordeau J, Fournier C, Johe K, Hazel T, et al. Transplantation of spinal cord-derived neural stem cells for ALS: Analysis of phase 1 and 2 trials. Neurology. 2016;87(4):392&#x2013;400.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4977116</ArticleId><ArticleId IdType="pubmed">27358335</ArticleId></ArticleIdList></Reference><Reference><Citation>Gouel F, Rolland AS, Devedjian JC, Burnouf T, Devos D. Past and future of neurotrophic growth factors therapies in ALS: from single neurotrophic growth factor to stem cells and human platelet lysates. Front Neurol. 2019;10(JUL):835.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6688198</ArticleId><ArticleId IdType="pubmed">31428042</ArticleId></ArticleIdList></Reference><Reference><Citation>Henriques A, Pitzer C, Schneider A. Book Neurotrophic growth factors for the treatment of amyotrophic lateral sclerosis: Where do we stand? (Editor ed.^eds.) 2010. Neurotrophic growth factors for the treatment of amyotrophic lateral sclerosis: Where do we stand?</Citation></Reference><Reference><Citation>Petrou P, Gothelf Y, Argov Z, Gotkine M, Levy YS, Kassis I, Vaknin-Dembinsky A, Ben-Hur T, Offen D, Abramsky O, et al. Safety and Clinical Effects of Mesenchymal Stem Cells Secreting Neurotrophic Factor Transplantation in Patients With Amyotrophic Lateral Sclerosis: Results of Phase 1/2 and 2a Clinical Trials. JAMA Neurol. 2016;73(3):337&#x2013;344.</Citation><ArticleIdList><ArticleId IdType="pubmed">26751635</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh KW, Moon C, Kim HY, Oh SI, Park J, Lee JH, Chang IY, Kim KS, Kim SH. Phase I trial of repeated intrathecal autologous bone marrow-derived mesenchymal stromal cells in amyotrophic lateral sclerosis. Stem Cells Transl Med. 2015;4(6):590&#x2013;597.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4449093</ArticleId><ArticleId IdType="pubmed">25934946</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh KW, Noh MY, Kwon MS, Kim HY, Oh SI, Park J, Kim HJ, Ki CS, Kim SH. Repeated Intrathecal Mesenchymal Stem Cells for Amyotrophic Lateral Sclerosis. Ann Neurol. 2018;84(3):361&#x2013;373.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6175096</ArticleId><ArticleId IdType="pubmed">30048006</ArticleId></ArticleIdList></Reference><Reference><Citation>Staff NP, Madigan NN, Morris J, Jentoft M, Sorenson EJ, Butler G, Gastineau D, Dietz A, Windebank AJ. Safety of intrathecal autologous adipose-derived mesenchymal stromal cells in patients with ALS. Neurology. 2016;87(21):2230&#x2013;2234.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5123559</ArticleId><ArticleId IdType="pubmed">27784774</ArticleId></ArticleIdList></Reference><Reference><Citation>Henkel JS, Beers DR, Wen S, Rivera AL, Toennis KM, Appel JE, Zhao W, Moore DH, Powell SZ, Appel SH. Regulatory T-lymphocytes mediate amyotrophic lateral sclerosis progression and survival. EMBO Mol Med. 2013;5(1):64&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3569654</ArticleId><ArticleId IdType="pubmed">23143995</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheean RK, McKay FC, Cretney E, Bye CR, Perera ND, Tomas D, Weston RA, Scheller KJ, Djouma E, Menon P, et al. Association of Regulatory T-Cell Expansion With Progression of Amyotrophic Lateral Sclerosis: A Study of Humans and a Transgenic Mouse Model. JAMA Neurol. 2018;75(6):681&#x2013;689.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5885208</ArticleId><ArticleId IdType="pubmed">29507931</ArticleId></ArticleIdList></Reference><Reference><Citation>Thonhoff JR, Beers DR, Zhao W, Pleitez M, Simpson EP, Berry JD, Cudkowicz ME, Appel SH. Expanded autologous regulatory T-lymphocyte infusions in ALS: A phase I, first-in-human study. Neurol Neuroimmunol Neuroinflamm. 2018;5(4):e465.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5961523</ArticleId><ArticleId IdType="pubmed">29845093</ArticleId></ArticleIdList></Reference><Reference><Citation>Vucic S. Differences in inflammatory profiles between ALS and FTD. J Neurol Neurosurg Psychiatry. 2019;90(1):1.</Citation><ArticleIdList><ArticleId IdType="pubmed">30224547</ArticleId></ArticleIdList></Reference><Reference><Citation>Khalid SI, Ampie L, Kelly R, Ladha SS, Dardis C. Immune Modulation in the Treatment of Amyotrophic Lateral Sclerosis: A Review of Clinical Trials. Front Neurol. 2017;8:486.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5622209</ArticleId><ArticleId IdType="pubmed">28993751</ArticleId></ArticleIdList></Reference><Reference><Citation>David S, Fry EJ, Lopez-Vales R. Novel roles for Nogo receptor in inflammation and disease. Trends Neurosci. 2008;31(5):221&#x2013;226.</Citation><ArticleIdList><ArticleId IdType="pubmed">18394723</ArticleId></ArticleIdList></Reference><Reference><Citation>Pernet V, Schwab ME. The role of Nogo-A in axonal plasticity, regrowth and repair. Cell Tissue Res. 2012;349(1):97&#x2013;104.</Citation><ArticleIdList><ArticleId IdType="pubmed">22588543</ArticleId></ArticleIdList></Reference><Reference><Citation>Berges A, Bullman J, Bates S, Krull D, Williams N, Chen C. Ozanezumab dose selection for amyotrophic lateral sclerosis by pharmacokinetic-pharmacodynamic modelling of immunohistochemistry data from patient muscle biopsies. PLoS One. 2015;10(2):e0117355.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4338135</ArticleId><ArticleId IdType="pubmed">25706882</ArticleId></ArticleIdList></Reference><Reference><Citation>Meininger V, Genge A, van den Berg LH, Robberecht W, Ludolph A, Chio A, Kim SH, Leigh PN, Kiernan MC, Shefner JM, et al. Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol. 2017;16(3):208&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pubmed">28139349</ArticleId></ArticleIdList></Reference><Reference><Citation>Quigley EMM. Microbiota-Brain-Gut Axis and Neurodegenerative Diseases. Curr Neurol Neurosci Rep. 2017;17(12):94.</Citation><ArticleIdList><ArticleId IdType="pubmed">29039142</ArticleId></ArticleIdList></Reference><Reference><Citation>Dinan TG, Cryan JF. The Microbiome-Gut-Brain Axis in Health and Disease. Gastroenterol Clin N Am. 2017;46(1):77&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pubmed">28164854</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang HX, Wang YP. Gut Microbiota-brain Axis. Chin Med J. 2016;129(19):2373&#x2013;2380.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5040025</ArticleId><ArticleId IdType="pubmed">27647198</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazzini L, Mogna L, De Marchi F, Amoruso A, Pane M, Aloisio I, Cionci NB, Gaggia F, Lucenti A, Bersano E, et al. Potential Role of Gut Microbiota in ALS Pathogenesis and Possible Novel Therapeutic Strategies. J Clin Gastroenterol. 2018;52(Suppl 1):S68&#x2013;S70.</Citation><ArticleIdList><ArticleId IdType="pubmed">29782468</ArticleId></ArticleIdList></Reference><Reference><Citation>McCombe PA, Henderson RD, Lee A, Lee JD, Woodruff TM, Restuadi R, McRae A, Wray NR, Ngo S, Steyn FJ. Gut microbiota in ALS: possible role in pathogenesis? Expert Rev Neurother. 2019;19(9):785&#x2013;805.</Citation><ArticleIdList><ArticleId IdType="pubmed">31122082</ArticleId></ArticleIdList></Reference><Reference><Citation>Blacher E, Bashiardes S, Shapiro H, Rothschild D, Mor U, Dori-Bachash M, Kleimeyer C, Moresi C, Harnik Y, Zur M, et al. Potential roles of gut microbiome and metabolites in modulating ALS in mice. Nature. 2019;572(7770):474&#x2013;480.</Citation><ArticleIdList><ArticleId IdType="pubmed">31330533</ArticleId></ArticleIdList></Reference><Reference><Citation>Benussi A, Alberici A, Cotelli MS, Dell'Era V, Cantoni V, Bonetta E, Manenti R, Filosto M, Morini R, Datta A, et al. Cortico-spinal tDCS in ALS: A randomized, double-blind, sham-controlled trial. Brain Stimul. 2019;12(5):1332&#x2013;1334.</Citation><ArticleIdList><ArticleId IdType="pubmed">31204206</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Lazzaro V, Pellegrino G, Ranieri F, Florio L, Musumeci G, Caulo M, Ferretti A, Capone F. Effects of repetitive TMS of the motor cortex on disease progression and on glutamate and GABA levels in ALS: A proof of principle study. Brain Stimul. 2017;10(5):1003&#x2013;1005.</Citation><ArticleIdList><ArticleId IdType="pubmed">28545769</ArticleId></ArticleIdList></Reference><Reference><Citation>Cotelli M, Manenti R, Petesi M, Brambilla M, Cosseddu M, Zanetti O, Miniussi C, Padovani A, Borroni B. Treatment of primary progressive aphasias by transcranial direct current stimulation combined with language training. J Alzheimers Dis. 2014;39(4):799&#x2013;808.</Citation><ArticleIdList><ArticleId IdType="pubmed">24296814</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor JP, Brown RH., Jr Cleveland DW Decoding ALS: from genes to mechanism. Nature. 2016;539(7628):197&#x2013;206.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5585017</ArticleId><ArticleId IdType="pubmed">27830784</ArticleId></ArticleIdList></Reference><Reference><Citation>Prasad A, Bharathi V, Sivalingam V, Girdhar A, Patel BK. Molecular Mechanisms of TDP-43 Misfolding and Pathology in Amyotrophic Lateral Sclerosis. Front Mol Neurosci. 2019;12:25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6382748</ArticleId><ArticleId IdType="pubmed">30837838</ArticleId></ArticleIdList></Reference><Reference><Citation>Butti Z, Patten SA. RNA Dysregulation in Amyotrophic Lateral Sclerosis. Front Genet. 2018;9:712.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6349704</ArticleId><ArticleId IdType="pubmed">30723494</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan AY, Manley JL. TLS/FUS: a protein in cancer and ALS. Cell Cycle. 2012;11(18):3349&#x2013;3350.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3466537</ArticleId><ArticleId IdType="pubmed">22918236</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan AY, Riley TR, Coady T, Bussemaker HJ, Manley JL. TLS/FUS (translocated in liposarcoma/fused in sarcoma) regulates target gene transcription via single-stranded DNA response elements. Proc Natl Acad Sci U S A. 2012;109(16):6030&#x2013;6035.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3341064</ArticleId><ArticleId IdType="pubmed">22460799</ArticleId></ArticleIdList></Reference><Reference><Citation>Lenzi J, De Santis R, de Turris V, Morlando M, Laneve P, Calvo A, Caliendo V, Chio A, Rosa A, Bozzoni I. ALS mutant FUS proteins are recruited into stress granules in induced pluripotent stem cell-derived motoneurons. Dis Model Mech. 2015;8(7):755&#x2013;766.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4486861</ArticleId><ArticleId IdType="pubmed">26035390</ArticleId></ArticleIdList></Reference><Reference><Citation>Radford RA, Morsch M, Rayner SL, Cole NJ, Pountney DL, Chung RS. The established and emerging roles of astrocytes and microglia in amyotrophic lateral sclerosis and frontotemporal dementia. Front Cell Neurosci. 2015;9:414.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4621294</ArticleId><ArticleId IdType="pubmed">26578880</ArticleId></ArticleIdList></Reference><Reference><Citation>Rostalski H, Leskela S, Huber N, Katisko K, Cajanus A, Solje E, Marttinen M, Natunen T, Remes AM, Hiltunen M, Haapasalo A. Astrocytes and Microglia as Potential Contributors to the Pathogenesis of C9orf72 Repeat Expansion-Associated FTLD and ALS. Front Neurosci. 2019;13:486.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6529740</ArticleId><ArticleId IdType="pubmed">31156371</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowland LP. Ameliorating amyotrophic lateral sclerosis. N Engl J Med. 2010;362(10):953&#x2013;954.</Citation><ArticleIdList><ArticleId IdType="pubmed">20220193</ArticleId></ArticleIdList></Reference><Reference><Citation>Benussi A, Alberici A, Buratti E, Ghidoni R, Gardoni F, Di Luca M, Padovani A, Borroni B. Toward a Glutamate Hypothesis of Frontotemporal Dementia. Front Neurosci. 2019;13:304.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6449454</ArticleId><ArticleId IdType="pubmed">30983965</ArticleId></ArticleIdList></Reference><Reference><Citation>Borroni B, Stanic J, Verpelli C, Mellone M, Bonomi E, Alberici A, Bernasconi P, Culotta L, Zianni E, Archetti S, et al. Anti-AMPA GluA3 antibodies in Frontotemporal dementia: a new molecular target. Sci Rep. 2017;7(1):6723.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5532270</ArticleId><ArticleId IdType="pubmed">28751743</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee EB, Lee VM, Trojanowski JQ. Gains or losses: molecular mechanisms of TDP43-mediated neurodegeneration. Nat Rev Neurosci. 2011;13(1):38&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3285250</ArticleId><ArticleId IdType="pubmed">22127299</ArticleId></ArticleIdList></Reference><Reference><Citation>Halliday G, Bigio EH, Cairns NJ, Neumann M, Mackenzie IR, Mann DM. Mechanisms of disease in frontotemporal lobar degeneration: gain of function versus loss of function effects. Acta Neuropathol. 2012;124(3):373&#x2013;382.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3445027</ArticleId><ArticleId IdType="pubmed">22878865</ArticleId></ArticleIdList></Reference><Reference><Citation>Buratti E. Functional Significance of TDP-43 Mutations in Disease. Adv Genet. 2015;91:1&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">26410029</ArticleId></ArticleIdList></Reference><Reference><Citation>Nana AL, Sidhu M, Gaus SE, Hwang JL, Li L, Park Y, Kim EJ, Pasquini L, Allen IE, Rankin KP, et al. Neurons selectively targeted in frontotemporal dementia reveal early stage TDP-43 pathobiology. Acta Neuropathol. 2019;137(1):27&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6339592</ArticleId><ArticleId IdType="pubmed">30511086</ArticleId></ArticleIdList></Reference><Reference><Citation>Cascella R, Capitini C, Fani G, Dobson CM, Cecchi C, Chiti F. Quantification of the Relative Contributions of Loss-of-function and Gain-of-function Mechanisms in TAR DNA-binding Protein 43 (TDP-43) Proteinopathies. J Biol Chem. 2016;291(37):19437&#x2013;19448.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5016682</ArticleId><ArticleId IdType="pubmed">27445339</ArticleId></ArticleIdList></Reference><Reference><Citation>Torrente MP, Chuang E, Noll MM, Jackrel ME, Go MS, Shorter J. Mechanistic Insights into Hsp104 Potentiation. J Biol Chem. 2016;291(10):5101&#x2013;5115.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4777845</ArticleId><ArticleId IdType="pubmed">26747608</ArticleId></ArticleIdList></Reference><Reference><Citation>Tariq A, Lin J, Noll MM, Torrente MP, Mack KL, Murillo OH, Jackrel ME, Shorter J. Potentiating Hsp104 activity via phosphomimetic mutations in the middle domain. FEMS Yeast Res. 2018;18(5):foy042.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6454557</ArticleId><ArticleId IdType="pubmed">29788207</ArticleId></ArticleIdList></Reference><Reference><Citation>Swarup V, Phaneuf D, Dupre N, Petri S, Strong M, Kriz J, Julien JP. Deregulation of TDP-43 in amyotrophic lateral sclerosis triggers nuclear factor kappaB-mediated pathogenic pathways. J Exp Med. 2011;208(12):2429&#x2013;2447.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3256969</ArticleId><ArticleId IdType="pubmed">22084410</ArticleId></ArticleIdList></Reference><Reference><Citation>Pozzi S, Thammisetty SS, Codron P, Rahimian R, Plourde KV, Soucy G, Bareil C, Phaneuf D, Kriz J, Gravel C, Julien JP. Virus-mediated delivery of antibody targeting TAR DNA-binding protein-43 mitigates associated neuropathology. J Clin Invest. 2019;129(4):1581&#x2013;1595.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6436898</ArticleId><ArticleId IdType="pubmed">30667370</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimura AL, Shum C, Scotter EL, Abdelgany A, Sardone V, Wright J, Lee YB, Chen HJ, Bilican B, Carrasco M, et al. Allele-specific knockdown of ALS-associated mutant TDP-43 in neural stem cells derived from induced pluripotent stem cells. PLoS One. 2014;9(3):e91269.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3961241</ArticleId><ArticleId IdType="pubmed">24651281</ArticleId></ArticleIdList></Reference><Reference><Citation>Borroni B, Bonvicini C, Alberici A, Buratti E, Agosti C, Archetti S, Papetti A, Stuani C, Di Luca M, Gennarelli M, Padovani A. Mutation within TARDBP leads to frontotemporal dementia without motor neuron disease. Hum Mutat. 2009;30(11):E974&#x2013;E983.</Citation><ArticleIdList><ArticleId IdType="pubmed">19655382</ArticleId></ArticleIdList></Reference><Reference><Citation>Khalfallah Y, Kuta R, Grasmuck C, Prat A, Durham HD, Vande VC. TDP-43 regulation of stress granule dynamics in neurodegenerative disease-relevant cell types. Sci Rep. 2018;8(1):7551.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5953947</ArticleId><ArticleId IdType="pubmed">29765078</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Cohen TJ. Aggregation of the nucleic acid-binding protein TDP-43 occurs via distinct routes that are coordinated with stress granule formation. J Biol Chem. 2019;294(10):3696&#x2013;3706.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6416430</ArticleId><ArticleId IdType="pubmed">30630951</ArticleId></ArticleIdList></Reference><Reference><Citation>De Conti L, Akinyi MV, Mendoza-Maldonado R, Romano M, Baralle M, Buratti E. TDP-43 affects splicing profiles and isoform production of genes involved in the apoptotic and mitotic cellular pathways. Nucleic Acids Res. 2015;43(18):8990&#x2013;9005.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4605304</ArticleId><ArticleId IdType="pubmed">26261209</ArticleId></ArticleIdList></Reference><Reference><Citation>Klim JR, Williams LA, Limone F, Guerra San Juan I, Davis-Dusenbery BN, Mordes DA, Burberry A, Steinbaugh MJ, Gamage KK, Kirchner R, et al. ALS-implicated protein TDP-43 sustains levels of STMN2, a mediator of motor neuron growth and repair. Nat Neurosci. 2019;22(2):167&#x2013;179.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7153761</ArticleId><ArticleId IdType="pubmed">30643292</ArticleId></ArticleIdList></Reference><Reference><Citation>Melamed Z, Lopez-Erauskin J, Baughn MW, Zhang O, Drenner K, Sun Y, Freyermuth F, McMahon MA, Beccari MS, Artates JW, et al. Premature polyadenylation-mediated loss of stathmin-2 is a hallmark of TDP-43-dependent neurodegeneration. Nat Neurosci. 2019;22(2):180&#x2013;190.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6348009</ArticleId><ArticleId IdType="pubmed">30643298</ArticleId></ArticleIdList></Reference><Reference><Citation>Appocher C, Mohagheghi F, Cappelli S, Stuani C, Romano M, Feiguin F, Buratti E. Major hnRNP proteins act as general TDP-43 functional modifiers both in Drosophila and human neuronal cells. Nucleic Acids Res. 2017;45(13):8026&#x2013;8045.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5570092</ArticleId><ArticleId IdType="pubmed">28575377</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker LA, Huang B, Bieri G, Ma R, Knowles DA, Jafar-Nejad P, Messing J, Kim HJ, Soriano A, Auburger G, et al. Therapeutic reduction of ataxin-2 extends lifespan and reduces pathology in TDP-43 mice. Nature. 2017;544(7650):367&#x2013;371.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5642042</ArticleId><ArticleId IdType="pubmed">28405022</ArticleId></ArticleIdList></Reference><Reference><Citation>Spiller KJ, Khan T, Dominique MA, Restrepo CR, Cotton-Samuel D, Levitan M, Jafar-Nejad P, Zhang B, Soriano A, Rigo F, et al. Reduction of matrix metalloproteinase 9 (MMP-9) protects motor neurons from TDP-43-triggered death in rNLS8 mice. Neurobiol Dis. 2019;124:133&#x2013;140.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7053168</ArticleId><ArticleId IdType="pubmed">30458231</ArticleId></ArticleIdList></Reference><Reference><Citation>Pons M, Prieto S, Miguel L, Frebourg T, Campion D, Sune C, Lecourtois M. Identification of TCERG1 as a new genetic modulator of TDP-43 production in Drosophila. Acta Neuropathol Commun. 2018;6(1):138.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6292132</ArticleId><ArticleId IdType="pubmed">30541625</ArticleId></ArticleIdList></Reference><Reference><Citation>Liachko NF, McMillan PJ, Strovas TJ, Loomis E, Greenup L, Murrell JR, Ghetti B, Raskind MA, Montine TJ, Bird TD, et al. The tau tubulin kinases TTBK1/2 promote accumulation of pathological TDP-43. PLoS Genet. 2014;10(12):e1004803.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4256087</ArticleId><ArticleId IdType="pubmed">25473830</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim HJ, Raphael AR, LaDow ES, McGurk L, Weber RA, Trojanowski JQ, Lee VM, Finkbeiner S, Gitler AD, Bonini NM. Therapeutic modulation of eIF2alpha phosphorylation rescues TDP-43 toxicity in amyotrophic lateral sclerosis disease models. Nat Genet. 2014;46(2):152&#x2013;160.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3934366</ArticleId><ArticleId IdType="pubmed">24336168</ArticleId></ArticleIdList></Reference><Reference><Citation>White MA, Kim E, Duffy A, Adalbert R, Phillips BU, Peters OM, Stephenson J, Yang S, Massenzio F, Lin Z, et al. TDP-43 gains function due to perturbed autoregulation in a Tardbp knock-in mouse model of ALS-FTD. Nat Neurosci. 2018;21(4):552&#x2013;563.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5884423</ArticleId><ArticleId IdType="pubmed">29556029</ArticleId></ArticleIdList></Reference><Reference><Citation>Fratta P, Polke JM, Newcombe J, Mizielinska S, Lashley T, Poulter M, Beck J, Preza E, Devoy A, Sidle K, et al. Screening a UK amyotrophic lateral sclerosis cohort provides evidence of multiple origins of the C9orf72 expansion. Neurobiol Aging. 2015;36(1):546 e541&#x2013;546 e547.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4270445</ArticleId><ArticleId IdType="pubmed">25179228</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizielinska S, Isaacs AM. C9orf72 amyotrophic lateral sclerosis and frontotemporal dementia: gain or loss of function? Curr Opin Neurol. 2014;27(5):515&#x2013;523.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4165481</ArticleId><ArticleId IdType="pubmed">25188012</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohrer JD, Isaacs AM, Mizielinska S, Mead S, Lashley T, Wray S, Sidle K, Fratta P, Orrell RW, Hardy J, et al. C9orf72 expansions in frontotemporal dementia and amyotrophic lateral sclerosis. Lancet Neurol. 2015;14(3):291&#x2013;301.</Citation><ArticleIdList><ArticleId IdType="pubmed">25638642</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y, Lin S, Staats KA, Li Y, Chang WH, Hung ST, Hendricks E, Linares GR, Wang Y, Son EY, et al. Haploinsufficiency leads to neurodegeneration in C9ORF72 ALS/FTD human induced motor neurons. Nat Med. 2018;24(3):313&#x2013;325.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6112156</ArticleId><ArticleId IdType="pubmed">29400714</ArticleId></ArticleIdList></Reference><Reference><Citation>Mis MSC, Brajkovic S, Tafuri F, Bresolin N, Comi GP, Corti S. Development of Therapeutics for C9ORF72 ALS/FTD-Related Disorders. Mol Neurobiol. 2017;54(6):4466&#x2013;4476.</Citation><ArticleIdList><ArticleId IdType="pubmed">27349438</ArticleId></ArticleIdList></Reference><Reference><Citation>Balendra R, Isaacs AM. C9orf72-mediated ALS and FTD: multiple pathways to disease. Nat Rev Neurol. 2018;14(9):544&#x2013;558.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6417666</ArticleId><ArticleId IdType="pubmed">30120348</ArticleId></ArticleIdList></Reference><Reference><Citation>Conlon EG, Manley JL. RNA-binding proteins in neurodegeneration: mechanisms in aggregate. Genes Dev. 2017;31(15):1509&#x2013;1528.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5630017</ArticleId><ArticleId IdType="pubmed">28912172</ArticleId></ArticleIdList></Reference><Reference><Citation>Zu T, Gibbens B, Doty NS, Gomes-Pereira M, Huguet A, Stone MD, Margolis J, Peterson M, Markowski TW, Ingram MA, et al. Non-ATG-initiated translation directed by microsatellite expansions. Proc Natl Acad Sci U S A. 2011;108(1):260&#x2013;265.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3017129</ArticleId><ArticleId IdType="pubmed">21173221</ArticleId></ArticleIdList></Reference><Reference><Citation>Simone R, Balendra R, Moens TG, Preza E, Wilson KM, Heslegrave A, Woodling NS, Niccoli T, Gilbert-Jaramillo J, Abdelkarim S, et al. G-quadruplex-binding small molecules ameliorate C9orf72 FTD/ALS pathology in vitro and in vivo. EMBO Mol Med. 2018;10(1):22&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5760849</ArticleId><ArticleId IdType="pubmed">29113975</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng W, Wang S, Zhang Z, Morgens DW, Hayes LR, Lee S, Portz B, Xie Y, Nguyen BV, Haney MS, et al. CRISPR-Cas9 Screens Identify the RNA Helicase DDX3X as a Repressor of C9ORF72 (GGGGCC)n Repeat-Associated Non-AUG Translation. Neuron. 2019;104(5):885&#x2013;898.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6895427</ArticleId><ArticleId IdType="pubmed">31587919</ArticleId></ArticleIdList></Reference><Reference><Citation>Jovicic A, Mertens J, Boeynaems S, Bogaert E, Chai N, Yamada SB, Paul JW, 3rd, Sun S, Herdy JR, Bieri G, et al. Modifiers of C9orf72 dipeptide repeat toxicity connect nucleocytoplasmic transport defects to FTD/ALS. Nat Neurosci. 2015;18(9):1226&#x2013;1229.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4552077</ArticleId><ArticleId IdType="pubmed">26308983</ArticleId></ArticleIdList></Reference><Reference><Citation>Freibaum BD, Lu Y, Lopez-Gonzalez R, Kim NC, Almeida S, Lee KH, Badders N, Valentine M, Miller BL, Wong PC, et al. GGGGCC repeat expansion in C9orf72 compromises nucleocytoplasmic transport. Nature. 2015;525(7567):129&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4631399</ArticleId><ArticleId IdType="pubmed">26308899</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang K, Donnelly CJ, Haeusler AR, Grima JC, Machamer JB, Steinwald P, Daley EL, Miller SJ, Cunningham KM, Vidensky S, et al. The C9orf72 repeat expansion disrupts nucleocytoplasmic transport. Nature. 2015;525(7567):56&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4800742</ArticleId><ArticleId IdType="pubmed">26308891</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Q, Lehmer C, Michaelsen M, Mori K, Alterauge D, Baumjohann D, Schludi MH, Greiling J, Farny D, Flatley A, et al. Antibodies inhibit transmission and aggregation of C9orf72 poly-GA dipeptide repeat proteins. EMBO Mol Med. 2017;9(5):687&#x2013;702.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5412769</ArticleId><ArticleId IdType="pubmed">28351931</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett CF, Krainer AR, Cleveland DW. Antisense Oligonucleotide Therapies for Neurodegenerative Diseases. Annu Rev Neurosci. 2019;42:385&#x2013;406.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7427431</ArticleId><ArticleId IdType="pubmed">31283897</ArticleId></ArticleIdList></Reference><Reference><Citation>St Martin JL, Wang L, Kaprielian Z. Toxicity in ALS: TDP-43 modifiers and C9orf72. Neurosci Lett. 2020;716:134621.</Citation><ArticleIdList><ArticleId IdType="pubmed">31726180</ArticleId></ArticleIdList></Reference><Reference><Citation>Riboldi G, Zanetta C, Ranieri M, Nizzardo M, Simone C, Magri F, Bresolin N, Comi GP, Corti S. Antisense oligonucleotide therapy for the treatment of C9ORF72 ALS/FTD diseases. Mol Neurobiol. 2014;50(3):721&#x2013;732.</Citation><ArticleIdList><ArticleId IdType="pubmed">24809691</ArticleId></ArticleIdList></Reference><Reference><Citation>Martier R, Liefhebber JM, Garcia-Osta A, Miniarikova J, Cuadrado-Tejedor M, Espelosin M, Ursua S, Petry H, van Deventer SJ, Evers MM, Konstantinova P. Targeting RNA-Mediated Toxicity in C9orf72 ALS and/or FTD by RNAi-Based Gene Therapy. Mol Ther Nucleic Acids. 2019;16:26&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6393708</ArticleId><ArticleId IdType="pubmed">30825670</ArticleId></ArticleIdList></Reference><Reference><Citation>Martier R, Liefhebber JM, Miniarikova J, van der Zon T, Snapper J, Kolder I, Petry H, van Deventer SJ, Evers MM, Konstantinova P. Artificial MicroRNAs Targeting C9orf72 Can Reduce Accumulation of Intra-nuclear Transcripts in ALS and FTD Patients. Mol Ther Nucleic Acids. 2019;14:593&#x2013;608.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6378669</ArticleId><ArticleId IdType="pubmed">30776581</ArticleId></ArticleIdList></Reference><Reference><Citation>Lagier-Tourenne C, Cleveland DW. Rethinking ALS: the FUS about TDP-43. Cell. 2009;136(6):1001&#x2013;1004.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3110083</ArticleId><ArticleId IdType="pubmed">19303844</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Langenhove T, van der Zee J, Sleegers K, Engelborghs S, Vandenberghe R, Gijselinck I, Van den Broeck M, Mattheijssens M, Peeters K, De Deyn PP, et al. Genetic contribution of FUS to frontotemporal lobar degeneration. Neurology. 2010;74(5):366&#x2013;371.</Citation><ArticleIdList><ArticleId IdType="pubmed">20124201</ArticleId></ArticleIdList></Reference><Reference><Citation>Naumann M, Peikert K, Gunther R, van der Kooi AJ, Aronica E, Hubers A, Danel V, Corcia P, Pan-Montojo F, Cirak S, et al. Phenotypes and malignancy risk of different FUS mutations in genetic amyotrophic lateral sclerosis. Ann Clin Transl Neurol. 2019;6(12):2384&#x2013;2394.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6917314</ArticleId><ArticleId IdType="pubmed">31682085</ArticleId></ArticleIdList></Reference><Reference><Citation>Shang Y, Huang EJ. Mechanisms of FUS mutations in familial amyotrophic lateral sclerosis. Brain Res. 1647;2016:65&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5003642</ArticleId><ArticleId IdType="pubmed">27033831</ArticleId></ArticleIdList></Reference><Reference><Citation>An H, Skelt L, Notaro A, Highley JR, Fox AH, La Bella V, Buchman VL, Shelkovnikova TA. ALS-linked FUS mutations confer loss and gain of function in the nucleus by promoting excessive formation of dysfunctional paraspeckles. Acta Neuropathol Commun. 2019;7(1):7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6330737</ArticleId><ArticleId IdType="pubmed">30642400</ArticleId></ArticleIdList></Reference><Reference><Citation>Murakami T, Qamar S, Lin JQ, Schierle GS, Rees E, Miyashita A, Costa AR, Dodd RB, Chan FT, Michel CH, et al. ALS/FTD Mutation-Induced Phase Transition of FUS Liquid Droplets and Reversible Hydrogels into Irreversible Hydrogels Impairs RNP Granule Function. Neuron. 2015;88(4):678&#x2013;690.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4660210</ArticleId><ArticleId IdType="pubmed">26526393</ArticleId></ArticleIdList></Reference><Reference><Citation>Marrone L, Drexler HCA, Wang J, Tripathi P, Distler T, Heisterkamp P, Anderson EN, Kour S, Moraiti A, Maharana S, et al. FUS pathology in ALS is linked to alterations in multiple ALS-associated proteins and rescued by drugs stimulating autophagy. Acta Neuropathol. 2019;138(1):67&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6570784</ArticleId><ArticleId IdType="pubmed">30937520</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossaert E, Pollari E, Jaspers T, Van Helleputte L, Jarpe M, Van Damme P, De Bock K, Moisse M, Van Den Bosch L. Restoration of histone acetylation ameliorates disease and metabolic abnormalities in a FUS mouse model. Acta Neuropathol Commun. 2019;7(1):107.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6612190</ArticleId><ArticleId IdType="pubmed">31277703</ArticleId></ArticleIdList></Reference><Reference><Citation>Guven G, Lohmann E, Bras J, Gibbs JR, Gurvit H, Bilgic B, Hanagasi H, Rizzu P, Heutink P, Emre M, et al. Mutation Frequency of the Major Frontotemporal Dementia Genes, MAPT, GRN and C9ORF72 in a Turkish Cohort of Dementia Patients. PLoS One. 2016;11(9):e0162592.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5025192</ArticleId><ArticleId IdType="pubmed">27632209</ArticleId></ArticleIdList></Reference><Reference><Citation>Rainero I, Rubino E, Michelerio A, D'Agata F, Gentile S, Pinessi L. Recent advances in the molecular genetics of frontotemporal lobar degeneration. Funct Neurol. 2017;32(1):7&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5505533</ArticleId><ArticleId IdType="pubmed">28380318</ArticleId></ArticleIdList></Reference><Reference><Citation>Wils H, Kleinberger G, Pereson S, Janssens J, Capell A, Van Dam D, Cuijt I, Joris G, De Deyn PP, Haass C, et al. Cellular ageing, increased mortality and FTLD-TDP-associated neuropathology in progranulin knockout mice. J Pathol. 2012;228(1):67&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">22733568</ArticleId></ArticleIdList></Reference><Reference><Citation>Gass J, Prudencio M, Stetler C, Petrucelli L. Progranulin: an emerging target for FTLD therapies. Brain Res. 2012;1462:118&#x2013;128.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3647886</ArticleId><ArticleId IdType="pubmed">22338605</ArticleId></ArticleIdList></Reference><Reference><Citation>Gass J, Lee WC, Cook C, Finch N, Stetler C, Jansen-West K, Lewis J, Link CD, Rademakers R, Nykjaer A, Petrucelli L. Progranulin regulates neuronal outgrowth independent of sortilin. Mol Neurodegener. 2012;7:33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3508877</ArticleId><ArticleId IdType="pubmed">22781549</ArticleId></ArticleIdList></Reference><Reference><Citation>Arrant AE, Onyilo VC, Unger DE, Roberson ED. Progranulin Gene Therapy Improves Lysosomal Dysfunction and Microglial Pathology Associated with Frontotemporal Dementia and Neuronal Ceroid Lipofuscinosis. J Neurosci. 2018;38(9):2341&#x2013;2358.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5830520</ArticleId><ArticleId IdType="pubmed">29378861</ArticleId></ArticleIdList></Reference><Reference><Citation>Prudencio M, Jansen-West KR, Lee WC, Gendron TF, Zhang YJ, Xu YF, Gass J, Stuani C, Stetler C, Rademakers R, et al. Misregulation of human sortilin splicing leads to the generation of a nonfunctional progranulin receptor. Proc Natl Acad Sci U S A. 2012;109(52):21510&#x2013;21515.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3535614</ArticleId><ArticleId IdType="pubmed">23236149</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohagheghi F, Prudencio M, Stuani C, Cook C, Jansen-West K, Dickson DW, Petrucelli L, Buratti E. TDP-43 functions within a network of hnRNP proteins to inhibit the production of a truncated human SORT1 receptor. Hum Mol Genet. 2016;25(3):534&#x2013;545.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4731020</ArticleId><ArticleId IdType="pubmed">26614389</ArticleId></ArticleIdList></Reference><Reference><Citation>Boxer AL, Gold M, Feldman H, Boeve BF, Dickinson SL, Fillit H, Ho C, Paul R, Pearlman R, Sutherland M, et al. New directions in clinical trials for frontotemporal lobar degeneration: Methods and outcome measures. Alzheimers Dement. 2020;16(1):131&#x2013;143.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6949386</ArticleId><ArticleId IdType="pubmed">31668596</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou ZY, Zhou ZR, Che CH, Liu CY, He RL, Huang HP. Genetic epidemiology of amyotrophic lateral sclerosis: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2017;88(7):540&#x2013;549.</Citation><ArticleIdList><ArticleId IdType="pubmed">28057713</ArticleId></ArticleIdList></Reference><Reference><Citation>Yanagi KS, Wu Z, Amaya J, Chapkis N, Duffy AM, Hajdarovic KH, Held A, Mathur AD, Russo K, Ryan VH, et al. Meta-analysis of Genetic Modifiers Reveals Candidate Dysregulated Pathways in Amyotrophic Lateral Sclerosis. Neuroscience. 2019;396:A3&#x2013;A20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6549511</ArticleId><ArticleId IdType="pubmed">30594291</ArticleId></ArticleIdList></Reference><Reference><Citation>FDA . Book Amyotrophic Lateral Sclerosis: Developing Drugs for Treatment Guidance for Industry (Editor ed.^eds.) 2019. Amyotrophic Lateral Sclerosis: Developing Drugs for Treatment Guidance for Industry.</Citation></Reference><Reference><Citation>Klim JR, Vance C, Scotter EL. Antisense oligonucleotide therapies for Amyotrophic Lateral Sclerosis: Existing and emerging targets. Int J Biochem Cell Biol. 2019;110:149&#x2013;153.</Citation><ArticleIdList><ArticleId IdType="pubmed">30904737</ArticleId></ArticleIdList></Reference><Reference><Citation>Colella P, Ronzitti G, Mingozzi F. Emerging Issues in AAV-Mediated In Vivo Gene Therapy. In: Book Emerging Issues in AAV-Mediated In Vivo Gene Therapy (Editor ed.^eds.), vol. 8: Cell Press; 2018. p. 87&#x2013;104. City.</Citation></Reference><Reference><Citation>Schoch KM, Miller TM. Antisense Oligonucleotides: Translation from Mouse Models to Human Neurodegenerative Diseases. Neuron. 2017;94(1097-4199 (Electronic)):1056&#x2013;1070.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5821515</ArticleId><ArticleId IdType="pubmed">28641106</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>